Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: A population based study

American Journal of Medical Genetics, Part A

Volumn 158 A, Issue 6, 2012, Pages 1269-1278

  Geirdal, Amy Østertun ^a,b   Dheyauldeen, Sinan ^b   Bachmann Harildstad, Gregor ^c   Heimdal, Ketil ^b  

^a OSLO METROPOLITAN UNIVERSITY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Epistaxis; Hereditary hemorrhagic telangiectasia; Norway; Nosebleeds; Population based; Quality of life

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ENDOGLIN;

ACTIVIN RECEPTOR LIKE KINASE 1 GENE; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENDOGLIN GENE; EPISTAXIS; FEMALE; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; ONSET AGE; PRIORITY JOURNAL; QUALITY OF LIFE; RENDU OSLER WEBER DISEASE; SHORT FORM 36;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NORWAY; QUALITY OF LIFE; QUESTIONNAIRES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84861223069     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.35309     Document Type: Article

References (33)

1. Atkinsen T. 1982. The stability and validity of quality of life measures. Soc Sci Med 10: 113-132.
2. Bideau A, Plauchu H, Brunet G, Robert JM. 1989. Epidemiological investigation of Rendu-Osler disease in France: Its geographical distribution and prevalence. Population 44: 3-22.
3. Biesecker BB, Erby L. 2008. Adaptation to living with a genetic condition or risk: A mini-review. Clin Genet 74: 401-407.
4. Cantril H. 1965. The pattern of human concerns. New Brunswick, NJ: Rutgers University Press.
5. Cohen JS, Biesecker BB. 2010. Quality of life in rare genetic conditions: A systematic review of the literature. Am J Med Genet Part A 152A: 1136-1156.
6. Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe M, Nozaki JI, Inoue S, Koizumi A. 2002. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 19: 140-148.
7. de Gussem EM, Snijder RJ, Disch FJ, Zanen P, Westermann CJ, Mager JJ. 2009. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: A pilot study. Rhinology 47: 85-88.
8. Dheyauldeen S, Abdelnoor M, Bachmann-Harildstad G. 2011. The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: A cross-sectional study. Am J Rhinol Allergy 25: 214-218.
9. Ferrans CE, Powers MJ. 1992. Psychometric assessment of the quality of life index. Res Nurs Health 15: 29-38.
10. Gandek B, Ware JE Jr, Aaronson NK, Alonso J, Apolone G, Bjorner J, Brazier J, Bullinger M, Fukuhara S, Kaasa S, Leplège A, Sullivan M. 1998. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: Results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51: 1149-1158.
11. Geisthoff UW, Heckmann K, D'Amelio R, Grunewald S, Knobber D, Falkai P, Konig J. 2007. Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 136: 726-733.
12. Guttmacher AE, Marchuk DA, White RI Jr, Guttmacher AE, Marchuk DA, White RI. 1995. Hereditary hemorrhagic telangiectasia. N Engl J Med 333: 918-924.
13. Jenkins LS, Brodsky M, Schron E, Chung M, Rocco TJ, Lader E, Constantine M, Sheppard R, Holmes D, Mateski D, Floden L, Prasun M, Greene HL, Shemanski L. 2005. Quality of life in atrial fibrillation: The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J 149: 112-120.
14. Karapantzos I, Tsimpiris N, Goulis DG, Van Hoecke H, Van Cauwenberge P, Danielides V. 2005. Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire. Eur Arch Otorhinolaryngol 262: 830-833.
15. Kjeldsen AD, Vase P, Green A. 1999. Hereditary haemorrhagic telangiectasia: A population-based study of prevalence and mortality in Danish patients. J Intern Med 245: 31-39.
16. Kjeldsen AD, Moller TR, Brusgaard K, Vase P, Andersen PE. 2005. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. J Intern Med 258: 349-355.
17. Lazarus RS, Folkman S, editors. 1984. Stress, appraisal, and coping. New York: Springer.
18. Lennox PA, Hitchings AE, Lund VJ, Howard DJ. 2005. The SF-36 health status questionnaire in assessing patients with epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 19: 71-74.
19. Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, Goizet C, Roume J, Rabilloud M, Saurin JC, Cottin V, Honnorat J, Coulet F, Giraud S, Calender A, Danesino C, Buscarini E, Plauchu H. 2007. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: Data from the French-Italian HHT network. Genet Med 9: 14-22.
20. Longacre AV, Gallitelli M, Henderson KJ, White RI Jr, Proctor DD. 2003. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 98: 59-65.
21. Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabba C. 2004. Health-related quality of life in a rare disease: Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber Disease. Qual Life Res 13: 1715-1723.
22. Peery WH. 1987. Clinical spectrum of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Am J Med 82: 989-997.
23. Pfister M, Zalaman IM, Blumenstock G, Mauz PS, Baumann I. 2009. Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Acta Otolaryngol 129: 862-866.
24. Sabba C, Gallitelli M, Pasculli G, Suppressa P, Resta F, Tafaro GE. 2006. HHT: A rare disease with a broad spectrum of clinical aspects. Curr Pharm Des 12: 1217-1220.
25. Shovlin C. 2000. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91: 66-67.
26. Simonds J, Miller F, Mandel J, Davidson TM. 2009. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 119: 988-992.
27. Slotosch D, Koller M, Werner JA, Folz BJ. 2006. Rezidivierende Epistaxis bei hereditärer hämorrhagischer Teleangiektasie. Isoliertes Symptom oder Einschränkung der Lebensqualität? Dtsch Med Wochenschr 131: 535-539.
28. Spilker B, editor. 1990. Introduction to the field of Quality of Life trials. New York: Raven Press. pp 3-10.
29. SSB. 2002. Survey of level of living statistics Norway.
30. Wagner AK, Gandek B, Aaronson NK, Acquadro C, Alonso J, Apolone G, Bullinger M, Bjorner J, Fukuhara S, Kaasa S, Leplège A, Sullivan M, Wood-Dauphinee S, Ware JE Jr. 1998. Cross-cultural comparisons of the content of SF-36 translations across 10 countries: Results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51: 925-932.
31. Ware JE Jr. 2000. SF-36 health survey update. Spine (PhilaPa 1976) 25: 3130-3139.
32. Ware JE, Snowk K, Kosinski M, Gandek B, editors. 1993. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Centre.
33. Ware J Jr, Kosinski M, Keller SD. 1996. A 12-Item short-form health survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34: 220-233.